重组人粒细胞刺激因子联合VDLP方案治疗费城染色体阴性急性淋巴细胞白血病患者的临床效果  

Clinical effect of Recombinant Human Granulocyte Stimulating Factor combined with VDLP regimen in the treatment of patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

作　　者：司艳辉[1] 王洋洋[1] 李冰[1] 黄鹏程[1] 李录克 SI Yan-hui;WANG Yang-yang;LI Bing;HUANG Peng-cheng;LI Lu-ke(Department of Hematology,the First People′s Hospital of Zhaoqing,Guangdong Province,Zhaoqing526060,China;Department of Hematology,General Hospital of Pingmei Shenma Medical Group,He′nan Province,Pingdingshan,467000,China)

机构地区：[1]广东省肇庆市第一人民医院血液科,广东肇庆526060 [2]平煤神马医疗集团总医院血液科,河南平顶山467000

出　　处：《中国当代医药》2020年第4期96-99,共4页China Modern Medicine

摘　　要：目的研究重组人粒细胞刺激因子联合VDLP方案治疗费城染色体阴性急性淋巴细胞白血病(ALL)患者的临床效果。方法选取2014年3月~2018年3月肇庆市第一人民医院和平煤神马医疗集团总医院收治的60例费城染色体阴性ALL患者作为研究对象,采用随机数字表法将其分为对照组和研究组,每组各30例。对照组患者采用VDLP方案治疗,研究组患者在对照组的基础上联合重组人粒细胞刺激因子治疗。比较两组患者的治疗效果、白细胞和中性粒细胞绝对值降低时间、不良反应总发生率及治疗前后生活质量(GQOLI-74)评分。结果研究组患者的总缓解率[70.00%(21/30)]高于对照组[43.33%(13/30)],差异有统计学意义(P<0.05)。研究组患者的白细胞和中性粒细胞绝对值降低时间均短于对照组,差异有统计学意义(P<0.05)。研究组患者的不良反应总发生率[6.67%(2/30)]低于对照组[26.67%(8/30)],差异有统计学意义(P<0.05)。治疗后,两组患者的心理功能、躯体功能、物质生活、社会功能评分均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05)。结论重组人粒细胞刺激因子联合VDLP方案治疗费城染色体阴性ALL患者,能有效提高治疗效果,缩短白细胞和中性粒细胞绝对值降低时间,降低不良反应发生率,改善患者预后。Objective To study the clinical effect of Recombinant Human Granulocyte Stimulating Factor combined with VDLP regimen in the treatment of patients with Philadelphia chromosome-negative acute lymphoblastic leukemia(ALL).Methods A total of 60 patients with Philadelphia chromosome-negative ALL admitted to the the First People′s Hospital of Zhaoqing and General Hospital of Pingmei Shenma Medical Group from March 2014 to March 2018 were selected as the study subjects,and they were divided into the control group and the study group according to the random number table method,30 cases in each group.The control group was treated with VDLP regimen,and the study group was treated with Recombinant Human Granulocyte Stimulating Factor on the basis of the control group.The therapeutic effect,the absolute reduction time of white blood cells and neutrophils,the total incidence rate of adverse reactions and quality of life(GQOLI-74)score before and after treatment were compared between the two groups.Results The total remission rate in the study group(70.00%[21/30])was higher than that in the control group(43.33%[13/30]),and the difference was statistically significant(P<0.05).The absolute reduction time of white blood cells and neutrophils in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.05).The total incidence rate of adverse reactions in the study group(6.67%[2/30])was lower than that in the control group(26.67%[8/30]),and the difference was statistically significant(P<0.05).After treatment,the psychological function,physical function,material life,and social function scores of the two groups were higher than those before treatment,and those in the study group were higher than those in the control group,with statistically significant differences(P<0.05).Conclusion Recombinant Human Granulocyte Stimulating Factor combined with VDLP regimen in the treatment of patients with Philadelphia chromosome-negative ALL can effectively improve the therapeutic effect, sho

关 键 词：费城染色体阴性急性淋巴细胞白血病 VDLP方案 重组人粒细胞刺激因子 不良反应 生活质量 

分 类 号：R730.51[医药卫生—肿瘤]